(0.28%) 5 536.75 points
(0.20%) 39 548 points
(0.31%) 19 990 points
(0.60%) $82.03
(-2.00%) $2.55
(0.24%) $2 345.20
(0.08%) $29.59
(-0.51%) $996.80
(-0.24%) $0.931
(-0.27%) $10.65
(-0.15%) $0.789
(1.95%) $87.40
Live Chart Being Loaded With Signals
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas...
Stats | |
---|---|
Šios dienos apimtis | 5.01M |
Vidutinė apimtis | 1.51M |
Rinkos kapitalizacija | 1.96B |
EPS | $-0.300 ( Q1 | 2024-05-08 ) |
Kita pelno data | ( $0.140 ) 2024-08-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-8.70 (Sector) 49.64 (Industry) 35.32 |
ATR14 | $0.00600 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-16 | Autor Deborah M. | Sell | 14 553 | Class A Common Stock |
2024-05-17 | Autor Deborah M. | Sell | 23 447 | Class A Common Stock |
2024-05-10 | Alva Emily Peterson | Buy | 76 453 | Class A Common Stock |
2024-05-10 | Alva Emily Peterson | Sell | 76 453 | Restricted Stock Units |
2024-05-10 | Autor Deborah M. | Buy | 76 453 | Class A Common Stock |
INSIDER POWER |
---|
-8.49 |
Last 100 transactions |
Buy: 155 690 540 | Sell: 179 138 765 |
Tūris Koreliacija
Amneal Pharmaceuticals Koreliacija
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Amneal Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Amneal Pharmaceuticals Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $2.39B |
Bruto pelnas: | $820.57M (34.28 %) |
EPS: | $-0.480 |
FY | 2023 |
Pajamos: | $2.39B |
Bruto pelnas: | $820.57M (34.28 %) |
EPS: | $-0.480 |
FY | 2022 |
Pajamos: | $2.21B |
Bruto pelnas: | $784.71M (35.47 %) |
EPS: | $-1.690 |
FY | 2021 |
Pajamos: | $2.09B |
Bruto pelnas: | $768.97M (36.73 %) |
EPS: | $0.0700 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.